Cure My Disease

Don't miss your cure!

 Log in / Sign up

A digital guide aims to help latinx cancer patients navigate genomic testing decisions

NCT ID NCT06476938

Knowledge-focused Sponsor: Fox Chase Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

Researchers are testing an online decision support tool called Gene PilotLX to see if it helps Latinx cancer patients make informed choices about tumor genomic testing. Tumor genomic testing looks for genetic changes in a tumor that might guide treatment or reveal hereditary risks. The trial will enroll 239 Latinx adults with solid tumor cancers at four cancer centers. Participants will use the tool or receive standard information, and researchers will measure how prepared they feel, how conflicted they are about the decision, and whether they talk with doctors and family about hereditary results.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Gene PilotLX, an eHealth decision support tool for tumor genomic profiling
What this could lead to
If it works, this tool could help Latinx cancer patients feel more prepared and less conflicted when deciding about tumor genomic testing, and improve communication with doctors and family about hereditary risks.
What could go wrong
This is an early-stage trial with a specific group, so results may not apply to all cancer patients. The tool's impact on actual decisions or health outcomes is not yet measured.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

239 people

The number who actually took part.

Started

May 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Self-identified Latinx patients who: 1. diagnosed with solid tumor cancers 2. speak/read English or Spanish; 3. can provide informed consent. Exclusion Criteria: Patients with hematologic/liquid cancers (leukemia, lymphoma, multiple myeloma, etc.)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

Contacts and locations

Locations

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Herbert Irving Comprehensive Cancer Center

    New York, New York, 10032, United States

  • MD Anderson Cancer Center at Cooper

    Camden, New Jersey, 08103, United States

  • Temple University Hospital

    Philadelphia, Pennsylvania, 19122, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.